Catalyst Pharmaceuticals, Inc.
CPRX
$24.79
$0.552.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.79% | 20.28% | 27.73% | 143.77% | 60.53% |
| Total Depreciation and Amortization | 0.84% | -0.37% | 0.26% | 0.32% | 3.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -310.14% | 242.27% | 67.00% | -88.60% | -74.15% |
| Change in Net Operating Assets | -441.06% | -249.70% | -89.06% | 18.46% | -41.90% |
| Cash from Operations | -36.66% | -55.49% | 11.17% | 88.08% | 27.37% |
| Capital Expenditure | 63.64% | 100.00% | -160.00% | -- | 99.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 63.64% | 100.00% | -160.00% | -- | 99.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.65% | 45.70% | 8.81% | -96.64% | 763.49% |
| Repurchase of Common Stock | -5,549.14% | -- | -- | -214.71% | -2.43% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.44% | 88.52% | -28.03% | 14.50% | -20.11% |
| Cash from Financing | -677.04% | 177.90% | -24.63% | -97.83% | 766.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.37% | -44.34% | 10.51% | -63.48% | 351.38% |